Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Bioconjugates labeled with alpha- and beta-particle emitting radionuclides as potential radiopharmaceuticals in Targeted Radionuclide Therapy.

2019/34/E/ST4/00080

Keywords:

radionuclides chelating ligands prosthetic groups nanobodies internalization HER2 targeted radionuclide therapy

Descriptors:

  • ST4_009:
  • ST4_018:
  • NZ7_014:

Panel:

ST4 - Chemistry: physical chemistry/chemical physics, theoretical chemistry, analytical chemistry, inorganic chemistry, organic chemistry, method development

Host institution :

Instytut Chemii i Techniki Jądrowej

woj. mazowieckie

Other projects carried out by the institution 

Principal investigator (from the host institution):

dr hab. Marek Pruszyński 

Number of co-investigators in the project: 5

Call: SONATA BIS 9 - announced on 2019-06-17

Amount awarded: 1 652 200 PLN

Project start date (Y-m-d): 2020-04-06

Project end date (Y-m-d): 2026-04-05

Project duration:: 72 months (the same as in the proposal)

Project status: Pending project

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

  • Publication in academic press/journals (2)
  1. Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HERpos cancer
    Authors:
    Rodak M, Dekempeneer Y, Wojewódzka M, Caveliers V, Covens P, Miller BW, Sevenois MB, Bruchertseifer F, Morgenstern A, Lahoutte T, D'Huyvetter M, Pruszyński M
    Academic press:
    Molecular Cancer Therapeutics (rok: 2022, tom: 21, strony: 1835–1845), Wydawca: American Association for Cancer Research
    Status:
    Published
    DOI:
    10.1158/1535-7163.MCT-21-0220 - link to the publication
  2. Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HERpos cancer
    Authors:
    Rodak M, Dekempeneer Y, Wojewódzka M, Caveliers V, Covens P, Miller BW, Sevenois MB, Bruchertseifer F, Morgenstern A, Lahoutte T, D'Huyvetter M, Pruszyński M
    Academic press:
    Molecular Cancer Therapeutics (rok: 2022, tom: 21, strony: 1835–1845), Wydawca: American Association for Cancer Research
    Status:
    Published
    DOI:
    10.1158/1535-7163.MCT-21-0220 - link to the publication

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy